A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†

Matthews, Gail V.; Avihingsanon, Anchalee; Lewin, Sharon R.; Amin, Janaki; Rerknimitr, Rungsun; Petcharapirat, Panusit; Marks, Pip; Sasadeusz, Joe; Cooper, David A.; Bowden, Scott; Locarnini, Stephen; Ruxrungtham, Kiat; Dore, Gregory J.

doi:10.1002/hep.22462

Cited by 125 publications

(137 citation statements)

References 27 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…TDF and LAM are highly effective medications for decreasing HBV viremia in patients infected only with HBV ) and in patients co-infected with HIV (Matthews et al 2008). Nevertheless, in patients already using LAM, the use of TDF can eventually lead to a slower decrease in HBV viremia.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

Silva

Spina

Lemos

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

In this study, we evaluated the hepatitis B virus (HBV) genotype distribution and HBV genomic mutations among a group of human immunodeficiency virus-HBV co-infected patients from an AIDS outpatient clinic in São Paulo. HBV serological markers were detected by commercially available enzyme immunoassay kits. HBV DNA was detected using in-house nested polymerase chain reaction and quantified by Cobas Amplicor. HBV genotypes and mutations in the basal core promoter (BCP)/pre-core/core regions and surface/polymerase genes were determined by sequencing. Among the 59 patients included in this study, 55 reported prior use of lamivudine (LAM) or tenofovir. HBV DNA was detected in 16/22 patients, with a genotype distribution of A (n = 12,75%), G (n = 2,13%), D (n = 1,6%) and F (n = 1,6%). The sequence data of the two patients infected with genotype G strongly suggested co-infection with genotype A. In 10 patients with viremia, LAM-resistance mutations in the polymerase gene (rtL180M + rtM204V and rtV173L + rtL180M + rtM204V) were found, accompanied by changes in the envelope gene (sI195M, sW196L and sI195M/sE164D). Mutations in the BCP and pre-core regions were identified in four patients. In conclusion, genotype G, which is rarely seen in Brazil, was observed in the group of patients included in our study. A high prevalence of mutations associated with LAM-resistance and mutations associated with anti-HBs resistance were also found among these patients

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

Silva

Spina

Lemos

et al. 2010

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…3TC/FTC-resistant strains will normally respond to tenofovir [118][119][120][121][122][123][134][135][136][137] Tenofovir is effective at suppressing HBV DNA and may induce HBeAg seroconversion although, as for other antivirals in coinfection, this may be less likely than in an HIV-negative person [127,[134][135][136]. Resistance is rare and combination with 3TC or FTC has been demonstrated to be effective at suppressing HBV DNA and may induce HBeAg seroconversion.…”

Section: Hiv Therapy Indicatedmentioning

confidence: 99%

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

et al. 2009

View full text Add to dashboard Cite

“…Matthews ve ark. 'nın [14] yapmış olduğu çalışmada ko-enfekte hastalarda tanı anındaki CD4+ lenfosit sayısı ortalaması 36 hücre/mm 3 iken 24. haftada 133 hücre/mm 3 , 48. haftada ise 202 hücre/mm 3 düzeyine yükseldiği saptanmıştır. Aynı çalışmada hastaların HBV DNA seviyeleri de gerilemiştir.…”

Section: Discussionunclassified

Seroprevalence of Hepatitis B and Hepatitis C Virus in HIV/AIDS Patients at Gaziantep University

Şahin¹,

Şahin²,

Namıduru³

et al. 2016

mjima

View full text Add to dashboard Cite

Giriş: İnsan immün yetmezlik virüsü (Human immunodeficiency virus-HIV) ya da AIDS (Edinsel İmmünYetmezlikIntroduction: Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) have major effect on the morbidity and mortality related with hepatitis B (HBV) and C virus (HCV) infections. Several observational studies suggest that HIV/HBV and HIV/HCV coinfected patients may have higher rates of fibrosis progression and an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma than patients with HBV and HCV infection alone. Hepatocellular carcinoma also occurs at an earlier age among HIV-infected patients compared to HIV-seronegative patients. In our study, we aimed to investigate the seroprevalence of HBV and HCV co-infections because of common transmission route in patients with HIV/AIDS. Materials and Methods: We retrospectively evaluated 113 HIV/AIDS patients followed by the Infectious Diseases and Clinical Microbiology Clinic at Gaziantep University Şahinbey Training and Application Hospital between 2011 and 2016. Demographic data of patients, HIV transmission routes, enzyme-linked immunosorbent assay results of HBV surface antigen (HBsAg), anti-HBsAg, anti-HBcAg immunoglobulin (Ig) total and anti-HCV serology, and real-time polymerase chain reaction results of serum HBV DNA and HCV RNA levels were obtained from patient records. Results: Ninety-four (83.2%) of 113 HIV/AIDS patients were male and 19 (16.8%) were female. The average age of the patients was 40.22±11.41 years. Eight patients (7%) were positive for HBsAg, 31 (27-4%) for anti-HBcAg total Ig, six (5%) for isolated anti-HBcAg Ig total 47 (41.5%) for anti-HBsAg and three (2.6%) subjects were positive for anti-HCV. All patients who were exposed to HBV were heterosexual. Of the three patients exposed to HCV, two (66.6%) were intravenous drug user. Symptoms of cirrhosis were not observed in HIV/HBV co-infected patients, while one HIV/HCV co-infected patient but one HIV/HCV co-infected patient. Conclusion: Because of the common transmission routes of HBV, HCV and HIV, serologic and virologic markers of hepatitis are necessary for both diagnosis and treatment of co-infections. Co-infection affects chronic hepatitis progression. This is important to avoid possible complications such as cirrhosis. Therefore, all patients with HIV infection should be followed for HBV and HCV.

show abstract

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†

Abstract: Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) isFrom the

Cited by 125 publications

References 27 publications

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

British HIV Association guidelines for the management of coinfection with HIV‐1 and hepatitis B or C virus 2010

Seroprevalence of Hepatitis B and Hepatitis C Virus in HIV/AIDS Patients at Gaziantep University

Contact Info

Product

Resources

About